Benzoyl Tropine

Benzoyl Tropine

SCHEMBL221830

CN1C2CCC1CC(OC(=O)c1ccccc1)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 3/20 1.00
HTR3B O95264 3/20 1.00
HTR3A P46098 3/20 1.00
HTR3D Q70Z44 3/20 1.00
HTR3C Q8WXA8 3/20 1.00
CHRNA7 P36544 3/20 1.00
CYP2D6 P10635 3/20 0.72
CYP2C19 P33261 2/20 0.72
LMNA P02545 1/20 0.72
POLB P06746 1/20 0.68
CYP1A2 P05177 2/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
NR1I2 O75469 1/20 0.67
GMNN O75496 1/20 0.65
ALOX15 P16050 1/20 0.65
TSHR P16473 1/20 0.65
MTOR P42345 1/20 0.65
PMP22 Q01453 1/20 0.65
HSD17B10 Q99714 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzoyl Tropine SCHEMBL30954638 1.00 HTR3E (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
Benzoyl Tropine SCHEMBL1103723 1.00 HTR3E (1.00) HTR3EHTR3BHTR3AHTR3DHTR3C
Benzoyl Tropine SCHEMBL3498565 0.98 HTR3E (0.97) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6500334 0.86 HTR3E (0.76) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6500328 0.86 HTR3E (0.76) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL7652481 0.86 HTR3A (0.75) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL7652475 0.86 HTR3A (0.75) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1851573 0.85 HTR3E (0.74) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6504512 0.85 CYP2D6 (0.97) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1851576 0.85 HTR3E (0.74) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319025-A9 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-16 US claimed
US-12419619-B2 Aspiration device YALE UNIVERSITY (US) 2025-09-23 US claimed
US-20250205278-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING ABBOTT NICHOLAS L (US) 2025-06-26 US claimed
WO-2025128639-A1 HYDROGELS COMPRISING PROTEIN-STABILIZED NANOPARTICLES FOR EXTENDED RELEASE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-19 WO claimed
WO-2025075976-A2 METHYL-BRANCHED LIPOSOMES FOR SUSTAINED DRUG DELIVERY THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-04-10 WO claimed
WO-2025059510-A1 COCA LEAF EXTRACT FOR NEUROPSYCHIATRIC DISORDERS MAGDALENA BIOSCIENCES, INC. (US) 2025-03-20 WO claimed
US-20250049711-A1 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-02-13 US claimed
US-12168026-B2 Methods and compositions for wound healing ABBOTT NICHOLAS L (US) 2024-12-17 US claimed
EP-4444274-A1 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF The Children's Medical Center Corporation (US) 2024-10-16 EP claimed
US-20240139237-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING ABBOTT NICHOLAS L (US) 2024-05-02 US claimed
EP-2001877-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT Bioniqs Limited (GB) 2008-12-17 EP claimed
EP-1931416-A2 IONTOPHORESIS METHOD AND APPARATUS FOR SYSTEMIC DELIVERY OF ACTIVE AGENTS TTI ELLEBEAU, INC. (JP) 2008-06-18 EP claimed
WO-2007110637-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT BIONIQS LIMITED (GB) 2007-10-04 WO claimed
US-20070093788-A1 Iontophoresis method and apparatus for systemic delivery of active agents TRANSCUTANEOUS TECHNOLOGIES INC. (JP) 2007-04-26 US claimed
WO-2007041300-A2 IONTOPHORESIS METHOD AND APPARATUS FOR SYSTEMIC DELIVERY OF ACTIVE AGENTS TTI ELLEBEAU, INC. (JP) 2007-04-12 WO claimed
EP-0687172-B1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF PHARMACIA AB (SE) 2002-12-04 EP claimed
US-6207178-B1 STABLE SUSPENSION KABI PHARMACIA AB (SE) 2001-03-27 US claimed
US-5785976-A Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof PHARMACIA & UPJOHN AB (SE) 1998-07-28 US claimed
EP-0687172-A1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF Pharmacia & Upjohn Aktiebolag (SE) 1995-12-20 EP claimed
WO-1994020072-A1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF PHARMACIA AB (SE) 1994-09-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250049711-A1 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF PHOSPHO1, SGMS1, LIPA HTR3E 2743/4885HTR3B 3036/4885HTR3A 2857/4885
US-20250319025-A9 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF PHOSPHO1, SGMS1, LIPA HTR3E 2743/4885HTR3B 3036/4885HTR3A 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.